FIGURE

Fig. 6

ID
ZDB-FIG-221106-20
Publication
Mohanty et al., 2022 - CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis
Other Figures
All Figure Page
Back to All Figure Page
Fig. 6

Lestaurtinib and 5FU synergistically reduced tumor burden in vivo in drug resistant OSCC.

A Patient-derived cells (PDC2) were earlier established from tumor of chemotherapy (TPF) non-responder patient. PDC2 were implanted in the right upper flank of athymic male nude mice, after which they were treated (i.p) with 5FU and/or Lestaurtinib at indicated concentrations. At the end of the experiment mice were euthanized, and tumors were isolated and photographed (n = 5). B Bar diagram indicates the tumor weight measured at the end of the experiment (mean ± SEM, n = 5). Two-way ANOVA, ****P < 0.0001. C Tumor growth was measured at the indicated time points using digital slide caliper and plotted as a graph (mean ± SEM, n = 5). Two-way ANOVA, ****P < 0.0001. D After completion of treatment, tumors were isolated, and paraffin-embedded sections were prepared as described in Methods to perform IHC with indicated antibodies. Scale bars: 50 μm. E Schematic presentation of the mechanism by which MINK1 regulates p53 expression through AKT/MDM2 axis.

Expression Data

Expression Detail
Antibody Labeling
Phenotype Data

Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Oncogene